A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with geographic atrophy (GA) secondary to age‐related macular degeneration (AMD) compared with sham control. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open‐label extension study NCT04607148 (GR42558) and receive open‐label galegenimab (FHTR2163) injections.
Epistemonikos ID: 72e78603101b2ea5cf2cfeedaad07448bc9624ed
First added on: May 22, 2024